Developer · United Kingdom

Monument Therapeutics Limited

Private precision-neuroscience company based in Manchester, UK, incubated by Cambridge Cognition from 2018 and spun out in July 2021. Develops novel formulations of well-characterised CNS-active small molecules, using digital cognitive biomarkers for patient stratification. Lead asset MT1988, a fixed-dose nicotinic combination for cognitive impairment associated with schizophrenia; earlier asset MT1980 targets neuroinflammation.

monumenttx.com ↗

2compounds
2programs
1indication
Phase 1/2lead asset

Phase distribution

  • Phase 1/21
  • Phase 11

Modality

  • Small molecule 2

Mechanism focus

Pipeline (2)

Deals & partnerships

  • Aug 19, 2025PartnershipMonument partners with FNIH to evaluate MT1988 within AMP SchizophreniaPartnership with the Foundation for the National Institutes of Health to run a randomised, placebo-controlled, IND-opening proof-of-principle trial of two MT1988 strengths vs placebo for 8 weeks in 150 participants at clinical high risk for psychosis, within the FNIH-managed Accelerating Medicines Partnership Schizophrenia (AMP SCZ) programme.MT1988 (tropisetron/varenicline)source ↗
  • Feb 25, 2025FinancingMonument Therapeutics secures GBP 850k to advance MT1988GBP 850k led by ACF Investors with Wren Capital, o2h Ventures and angel investors, to fund the schizophrenia programme and progress MT1988 through further clinical development.MT1988 (tropisetron/varenicline)source ↗
  • Oct 15, 2024FinancingMonument Therapeutics secures GBP 1M equity investment from the Forster FoundationGBP 1M further equity investment from the Forster Foundation to support clinical development of MT1988 for cognitive symptoms of schizophrenia.MT1988 (tropisetron/varenicline)source ↗
  • Dec 14, 2021FinancingMonument Therapeutics raises an additional GBP 0.5 million to take MT1980 into the clinicMonument raised an additional GBP 0.5 million to accelerate MT1980, then aimed at post-operative cognitive decline (POCD), and to bring the first human study forward to mid-2022.MT1980source ↗

Catalysts · 1 upcoming · 2 reported

Recently reported

  • 2025-06-23met

    MT1988 (tropisetron/varenicline)forSchizophreniaTopline data

    Phase 1 multiple-dose study of MT1988 in healthy adults: generally well tolerated with no severe or serious adverse events; supports advancement into Phase II.

    source ↗

  • 2023-01-09met

    MT1980forSchizophreniaTopline data

    First-in-human single-dose Phase 1 of MT1980 met all objectives: drug was found in the cerebrospinal fluid of every healthy volunteer, and there were no significant MT1980-related side effects.

    source ↗

Recent activity

  • Mar 3, 2026Phase changeMT1988 (tropisetron/varenicline)·SchizophreniaPhase 1/2Phase 1/2 proof-of-principle study NCT07226895 in participants at clinical high risk for psychosis started (registry actual start 2026-03-03); Monument announced first patient dosed on 2026-03-10.source ↗
  • Jun 23, 2025ReadoutMT1988 (tropisetron/varenicline)·SchizophreniametPhase 1 multiple-dose study of MT1988 in healthy adults: generally well tolerated with no severe or serious adverse events; supports advancement into Phase II.source ↗
  • Apr 8, 2025Phase changeMT1988 (tropisetron/varenicline)·SchizophreniaPhase 1Phase 1 primary completion (actual) per registry; Monument announced positive Phase I results on 2025-06-23 (generally well tolerated, no severe or serious AEs).source ↗
  • Nov 25, 2024Phase changeMT1988 (tropisetron/varenicline)·SchizophreniaPhase 1First clinical study of MT1988 started: Phase 1 multiple-dose safety/PK study in healthy adults (NCT06728176, SCZ103) at BDD Pharma; announced 2024-11-26.source ↗
  • Jan 9, 2023ReadoutMT1980·SchizophreniametFirst-in-human single-dose Phase 1 of MT1980 met all objectives: drug was found in the cerebrospinal fluid of every healthy volunteer, and there were no significant MT1980-related side effects.source ↗
  • Oct 4, 2022Phase changeMT1980·SchizophreniaPhase 1NCT05429840 completed (actual primary completion 2022-10-04, 24 participants). Monument reported on 2023-01-09 that the study met all objectives. A multiple-dose Phase 1 has been planned since then but is not registered.source ↗
  • Jun 1, 2022Phase changeMT1980·SchizophreniaPhase 1First-in-human single-dose Phase 1 NCT05429840 (protocol PCD101) started per ClinicalTrials.gov. It enrolled healthy volunteers and was registered under 'Neuroinflammatory Response', not schizophrenia. Monument announced the start on 2022-06-13.source ↗

Trials recruiting · 1 recruiting of 3 sponsored

    Showing 0 of 1 recruiting trials.

    Competitive landscape

    Other companies developing against Monument Therapeutics Limited's targets or indications.